Today: 18 January 2026
Subscribe
Browse Category

Biotech News 31 December 2025 - 6 January 2026

Alumis stock jumps 129% after Phase 3 psoriasis data; ALMS hits new 52-week high

Alumis stock jumps 129% after Phase 3 psoriasis data; ALMS hits new 52-week high

New York, January 6, 2026, 09:49 EST — Regular session Alumis Inc (ALMS) shares jumped about 129% in early trade on Tuesday after the drugmaker reported positive late-stage data for its psoriasis pill, envudeucitinib. The stock was at $19.04, up from a previous close of $8.31, after touching $22.30 to set a new 52-week high, Google Finance data showed. Google…
6 January 2026
···
Zenas BioPharma stock slides again premarket after INDIGO Phase 3 data sparks fresh scrutiny

Zenas BioPharma stock slides again premarket after INDIGO Phase 3 data sparks fresh scrutiny

New York, January 6, 2026, 08:44 EST — Premarket Zenas BioPharma (ZBIO.O) shares were down 5.8% at $15.66 in premarket trading on Tuesday after ending Monday down 51.9% at $16.61. MarketScreener The slide follows a late-stage readout for the company’s lead drug obexelimab in IgG4-related disease (IgG4-RD), a rare immune condition that can inflame and scar organs. Zenas met the…
6 January 2026
····
Kymera Therapeutics stock extends slide as KYMR closes down 6.5% — what investors watch next

Kymera Therapeutics stock extends slide as KYMR closes down 6.5% — what investors watch next

NEW YORK, Jan 4, 2026, 11:20 ET — Market closed Kymera Therapeutics, Inc. (KYMR) shares closed down 6.5% on Friday at $72.76, extending a losing streak to seven consecutive sessions as the U.S. market heads into the first full trading week of 2026. The stock is down about 13% since Dec. 23 and roughly 29% below the record intraday high…
4 January 2026
····
Dyne Therapeutics (DYN) stock slides today as biotech wobbles — FDA clock back in focus

Dyne Therapeutics (DYN) stock slides today as biotech wobbles — FDA clock back in focus

NEW YORK, Jan 2, 2026, 3:19 PM ET — Regular session Dyne Therapeutics shares fell about 6% on Friday, giving back earlier gains in a volatile first session of 2026 for some biotech names. The Nasdaq-listed stock was down 6.1% at $18.36 in afternoon trading, after touching $20.90 at the high and $18.13 at the low. The move matters because…
2 January 2026
···
SELLAS (SLS) stock jumps about 10% in premarket as REGAL AML trial milestone stays in focus

SELLAS (SLS) stock jumps about 10% in premarket as REGAL AML trial milestone stays in focus

NEW YORK, January 2, 2026, 05:03 ET — Premarket SELLAS Life Sciences Group (SLS) shares rose about 10% in U.S. premarket trading on Friday to $4.14, after gaining 13.9% in the prior regular session. Early trading ranged between $4.13 and $4.32. Public The move matters because SELLAS’ valuation hinges on a single late-stage cancer study, and timing signals can drive…
2 January 2026
····
AXSM stock jumps after FDA sets April 30 decision date for Axsome’s AXS-05 in Alzheimer’s agitation

AXSM stock jumps after FDA sets April 30 decision date for Axsome’s AXS-05 in Alzheimer’s agitation

NEW YORK, January 1, 2026, 21:06 ET — Market closed Axsome Therapeutics shares jumped 22.9% in the Dec. 31 session, ending at $182.64 after the company disclosed two U.S. FDA updates that put near-term regulatory milestones back in focus. The stock traded between $148.79 and $184.40 on the day, with about 3.1 million shares changing hands. The move matters because…
2 January 2026
···
Corcept Therapeutics stock tanks on FDA relacorilant setback — what happens next for CORT

Corcept Therapeutics stock tanks on FDA relacorilant setback — what happens next for CORT

NEW YORK, January 1, 2026, 3:46 PM ET — Market closed. Corcept Therapeutics (CORT.O) shares ended the last U.S. session down 50.4% at $34.80 after the Food and Drug Administration declined to approve the company’s drug relacorilant for a rare hormonal-disorder-related blood-pressure condition. StockAnalysis U.S. stock markets are closed on Thursday for New Year’s Day, leaving investors to digest the…
1 January 2026
····
Healthcare stocks today: FDA decisions jolt biotechs as Wall Street shuts for New Year

Healthcare stocks today: FDA decisions jolt biotechs as Wall Street shuts for New Year

NEW YORK, January 1, 2026, 13:41 ET — Market closed Vanda Pharmaceuticals’ FDA win in motion sickness set the tone for outsized, stock-specific swings in healthcare shares as Wall Street paused for the New Year’s Day holiday. U.S. stock markets were closed Thursday. Nasdaq The moves matter because regulatory calls can dominate small-cap biotech even when the broader healthcare sector…
1 January 2026
···
Genmab stock slides today as GMAB shelves acasunlimab; Merus takeout steps in focus

Genmab stock slides today as GMAB shelves acasunlimab; Merus takeout steps in focus

NEW YORK, December 31, 2025, 11:38 ET — Regular session Genmab A/S (GMAB) shares slid on Wednesday, down about 3.3% at $30.44 in New York trading, as investors weighed a late-stage pipeline cut and the closing steps of a major acquisition. The Nasdaq-listed ADR touched $30.36 after opening at $31.42. Genmab said on Dec. 29 it will discontinue further clinical…
31 December 2025
···
Ultragenyx stock today: RARE steadies premarket after setrusumab Phase 3 miss, FDA gene-therapy filing in focus

Ultragenyx stock today: RARE steadies premarket after setrusumab Phase 3 miss, FDA gene-therapy filing in focus

NEW YORK, December 31, 2025, 09:15 ET — Premarket Ultragenyx Pharmaceutical (RARE.O) shares edged down 0.2% to $22.74 in premarket trading on Wednesday, after finishing Tuesday up 15.5% at $22.78. The stock’s 52-week range is $18.41 to $46.50. StockAnalysis The rare-disease drugmaker is trying to find its footing after a sharp two-day repricing driven by a late-stage clinical setback that…
31 December 2025
···
1 2 3 4 … 12

Stock Market Today

  • NNN REIT trades at discount to DCF-based value; price US$42.64 vs intrinsic US$77.61
    January 18, 2026, 12:18 PM EST. NNN REIT trades at US$42.64, with 7-day, 30-day and YTD gains of 3.9%, 7.2% and 7.9%. Over 1 year it's up 12.8% and 5 years 37.6%. Simply Wall St assigns a valuation score of 5/6, citing the stock as undervalued on most checks. A two-stage DCF framework uses trailing free cash flow of about $616.6 million and projects $977.6 million in 2035, yielding an intrinsic value of US$77.61 per share and a 45.1% discount to the current price. The takeaway is that the stock looks undervalued on this model, though investors weigh the stability of a REIT against growth prospects; outcomes depend on cash-flow assumptions.
Go toTop